Aim: MUC-1 lipopeptide vaccine exhibited immense potential in the treatment of non-small cell lung cancer (NSCLC) in both preclinical and clinical trials. However, it lacks triggering of mucosal immunity at the site of action. Therefore, in present investigation, MUC-1 peptide-loaded poly(lactide-co-glycolide) nanoparticles (MUC-1 peptide-PLGA-NPs) and MUC-1 peptide-loaded poly(lactide-co-glycolide) non-aggregated nanoparticles (MUC-1 peptide-PLGA-NA-NPs) using Central Composite Design (CCD) were customised.Methods and Results: The mean particle size of MUC-1 peptide PLGA-NPs was estimated to be 176.7 ± 32.7 nm, significantly (p < 0.05) higher than 100.3 ± 24.3 nm of MUC-1 peptide-PLGA-NA-NPs. Furthermore, integrity and stability of MUC-1 were maintained in MUC-1 peptide PLGA-NA-NPs. MUC-1 peptide-PLGA-NA-NPs exhibited augmented cellular uptake in mouse RAW264.7 macrophages preferably by clathrin-mediated endocytosis pathway as compared to phagocytosis followed by MUC-1-peptide PLGA-NPs owing to size ≤100 nm, and spherical shape.Conclusion: MUC-1 peptide-PLGA-NA-NPs may be a potential candidate to study antitumor potential in xenograft model of NSCLC through inhalation route of administration.

中文翻译：

---

非小细胞肺癌肿瘤抗原，负载MUC-1肽的非聚集型聚（丙交酯-乙交酯）纳米粒子增加了小鼠专业抗原呈递细胞的细胞摄取：优化和表征。

目的：MUC-1脂肽疫苗在临床前和临床试验中均显示出治疗非小细胞肺癌（NSCLC）的巨大潜力。但是，它在作用部位缺乏触发粘膜免疫的能力。因此，在本研究中，MUC-1肽负载的聚丙交酯-乙交酯共聚物纳米粒子（MUC-1肽-PLGA-NPs）和MUC-1肽负载的聚丙交酯-乙交酯共聚物非聚集纳米粒子方法和结果：MUC-1肽PLGA-NP的平均粒径估计为176.7±32.7 nm，显着（p <0.05）高于100.3±24.3 nm的MUC-1肽-PLGA-NA-NPs。此外，在MUC-1肽PLGA-NA-NP中保持了MUC-1的完整性和稳定性。